Fuchs B, Bartolomeo R S
Clin Ther. 1982;5(2):179-85.
Ten patients with gastroesophageal reflux disease participated in a randomized, double-blind, crossover study in which they received a single 20-mg oral dose of metoclopramide or a placebo 15 minutes before a provocative test meal. All patients had previously been challenged with the test meal and had exhibited symptoms of heartburn and regurgitation. Metoclopramide reduced the severity of heartburn from the onset, its effect reaching statistical significance within two hours and persisting for at least five hours. Eighty percent of the patients who received metoclopramide, compared with only 30% of placebo-treated patients, were completely free of heartburn at the end of the trial. A significant reduction in regurgitation during the 1 1/2 to four hours after the test meal was also noted with metoclopramide. No adverse effects occurred. The ability of metoclopramide to prevent the symptoms of heartburn and regurgitation induced by a provocative meal in patients with gastroesophageal reflux was clearly demonstrated.
10名胃食管反流病患者参与了一项随机、双盲、交叉研究，在激发试验餐前进食15分钟时，他们接受了单次20毫克的甲氧氯普胺口服剂量或安慰剂。所有患者此前均接受过试验餐挑战，并出现过烧心和反流症状。甲氧氯普胺从一开始就减轻了烧心的严重程度，其效果在两小时内达到统计学意义，并持续至少五小时。在试验结束时，接受甲氧氯普胺治疗的患者中有80%完全没有烧心症状，而接受安慰剂治疗的患者中这一比例仅为30%。还注意到，在试验餐后1.5至4小时内，甲氧氯普胺使反流显著减少。未出现不良反应。甲氧氯普胺预防胃食管反流患者激发餐诱发的烧心和反流症状的能力得到了明确证明。
